Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: BOŃSKI
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/1

Tytuł oryginału: Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Autorzy: Robak Tadeusz, Boński Jerzy Z., Kasznicki Marek, Góra-Tybor Joanna, Hellmann Andrzej, Konopka Lech, Dmoszyńska Anna, Dwilewicz-Trojaczek Jadwiga, Wołowiec Dariusz
Źródło: Eur. J. Haematol. 2002: 69 (1) s.27-36, il., tab., bibliogr. 39 poz.
Sygnatura GBL: 304,912

Hasła klasyfikacyjne GBL:
  • toksykologia
  • hematologia
  • onkologia

    Typ dokumentu:
  • praca kliniczna
  • badanie porównawcze
  • praca opublikowana za granicą
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • dorośli 19-44 r.ż.
  • dorośli 45-64 r.ż.
  • dorośli = 65 r.ż.
  • płeć męska
  • płeć żeńska

    Streszczenie angielskie: The aim of the study was to determine the effectiveness and toxicity of cladribine (2-CdA) used alone or in combination with prednisone (P) or cyclophosphamide and mitoxantrone in te-treatment of patients with progressive B-cell chronic lymphocytic leukemia (B-CLL). We analyzed treatment outcome in 40 patients who had responded to previous treatment with 2-Cd-A-based regimens. Criteria for re-treatment were the same as for the first treatment. The patients were retreated with the same agents if they responded to the first treatment and then relapsed with progressive disease not earlier than 3 months after achieving the first response. Eight patients received 2-CdA alone (0.12 mg kg-1 d-1) i.v. for 5 d, and 21 patients additionally were given P (30 mg m-2 d-1) orally, also for 5 d. Eleven patients received 2-CdA for 3 d combined with cyclophosphamide (650 mg m-2) i.v. and mitoxantrone (10 mg m-2) i.v. on day 1 (CMC regimen). The cycles were repeated usually at 4 wk intervals or longer if severe myelosuppression or infections occurred. The therapy was finished if complete remission (CR) was achieved or until maximum of sic courses. Overall response (IR) in re-treatment was obtained in 16 out of 40 (40 p.c.) patients (95 p.c. CI 16-64), including 62 p.c. after 2-CdA, 33 p.c. after 2-CdA + P and 36 p.c. after CMC. CR was obtained in four (10 p.c.) patients. Residual disease evaluated in the patients with CR by surface immunophenotyping had been demonstrated in 5 out of 16 (31 p.c.) patients after the first treatment and in one out of four (25 p.c.) patients after re-treatment. The median...

    stosując format: